Content
All Posts > Content under Pharma/Biotech
Why Is This Stock Going Up When Financials Are Down
Article By:
Investing Whisperer
Read
Sunday, December 22, 2019 5:36 PM EDT
Stereotaxis is a medical device company with flat to declining revenue…yet the stock has quadrupled in 2019. The stock has more to do with a competitive takeover at 60x sales than its own financials.
IWM Waking Up Could Spark SPY, QQQ And Dow Rally
Article By:
Michele Schneider
Read
Sunday, December 22, 2019 1:00 PM EDT
Should the Russell 2000 IWM wake up, the rally in SPY, QQQs, and the Dow would be exponential. Furthermore, it would be the healthiest sign for the market since September 2018, right before the 20% sell-off.
Week In Review: Ally Bridge Leads $140 Million Of Investments In Three Medical Device Companies
Article By:
ChinaBio® Today
Read
Saturday, December 21, 2019 5:09 PM EDT
Ally Bridge Group, a Hong Kong-New York life science investment firm, announced it has led $140 million of investments in three new medical device companies, bringing its 18-month total to more than $500 million in private life science companies.
Nabriva Therapeutics Announces $20 Million Registered Direct Offering
Article By:
NASDAQ GlobeNewswire
Read
Friday, December 20, 2019 10:13 AM EDT
Nabriva Therapeutics plc today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale in a registered direct offering of an aggregate of 13,793,106 ordinary shares.
In this article: NBRV
Jefferies Gives European Investors 'Christmas List Of 20 Stocks For 2020'
Week In Review: AlphaMab Raises $234 Million In Hong Kong IPO; Climbs 35% In First Trading Session
Article By:
ChinaBio® Today
Read
Saturday, December 14, 2019 5:09 PM EDT
Alphamab Oncology raised $234 million in a Hong Kong IPO and traded 35% higher from its offering price to a market cap of $1.2 billion. The company has a PD-L1 candidate that could be approved in China in 2020 and two bispecifics in Phase II tests.
Madrigal Pharmaceuticals Announces Pricing Of Secondary Offering
Article By:
NASDAQ GlobeNewswire
Read
Tuesday, December 10, 2019 10:18 PM EDT
Madrigal Pharmaceuticals, Inc. today announced the pricing of the previously-announced underwritten secondary offering by investment funds affiliated with Bay City Capital LLC, of 1,200,000 shares of Madrigal’s common stock.
In this article: MDGL